• Represented numerous life sciences companies facing securities litigation and derivative litigation following the Food and Drug Administration's rejection of new drug applications; obtained outright dismissal of majority of complaints on motions to dismiss. Several dismissals were affirmed by Federal Courts of Appeals.
    • Successfully litigated a large number of derivative and class actions challenging M&A litigation throughout the country, including successful enforcement of a forum selection clause through use of anti-suit injunction in Delaware Chancery Court. Convinced Michigan Court of Appeals and Illinois Court of Appeals to affirm dismissals of merger related litigation following oral arguments.
    • Represent special litigation committee in an extensive investigation of alleged bribery of a public official and subsequent litigation in federal court.
    • Obtained dismissal of securities fraud claims against national beverage company arising out of a hundreds of millions of dollar restatement.
    • Obtained dismissal of fraud claims against former CFO of large shipping company, successfully litigated related securities fraud claims and SEC investigation.
    • Defeated securities fraud claims against former CEO of large grocery store chain.
    • Obtained dismissal of a derivative action pending in federal court against a prominent credit card company based on alleged improper marketing practices.
    • Obtained dismissal of derivative claims against special litigation committee of large oil and gas company.
    • Successfully defeated derivative action alleging breaches of fiduciary duty brought against former chair of an audit committee.
    • Obtained dismissal of fraud and misrepresentation claims against large manufacturer pending in New York state court.
    • Successfully represented prominent chemical company in highly contested securities fraud litigation and employed strategic electronic discovery tactics to streamline discovery process.
    • In conjunction with LAMBDA Legal, provided pro bono representation for individuals seeking to retroactively enforce effect of Obergefell decision on social security benefits. Reached favorable settlement.
    • Represented numerous pro bono clients seeking compassionate release from federal prison as a result of risks posed by COVID-19 and underlying health conditions.
    • Leads Dechert’s efforts to support Advocates for Human Rights in advocacy before the United Nations relating to abolishment of the death penalty and other inhumane conditions in various countries, including submission of over ten reports to the United Nations.
    • Cryptocurrency Securities Class Action Litigation: 2023 Year in Review, The Review of Securities & Commodities Regulation, April 10, 2024
    • Crypto Securities Class Action Filings Will Follow Market Trends, Bloomberg Law, March 14, 2024
    • Quoted, Del. Courts Saw APE Wars, Fox Fury and a Barr Fight in 2023Law360, December 20, 2023
    • How Life Sciences Cos. Can Prevent Securities Class Actions, Law360, October 12, 2023
    • Chancery Court Finds for Oracle Founder and CEO in Post-Trial Decision, Harvard Law School Forum on Corporate GovernanceJuly 3, 2023
    • Recent Trends in US Securities and Derivative LitigationFinancier Worldwide, June 1, 2021
    • 2022 Developments in U.S. Securities Fraud Class Actions Against Non-U.S. Issuers, Harvard Law School Forum on Corporate GovernanceApril 12, 2023
    • 2022 Edition: Developments in Securities Fraud Class Actions Against U.S. Life Sciences Companies, Dechert Survey, February 23, 2023
    • Developments in Securities Fraud Class Actions Against U.S. Life Sciences Companies, Dechert Survey, March 28, 2022
    • Developments in U.S. Securities Fraud Class Action Lawsuits Against Non-U.S. Issuers — 2021 Summary, February 24, 2022
    • 2020 Developments in Securities Fraud Class Actions Against Non-U.S. IssuersHarvard Law School Forum on Corporate Governance, March 23, 2021
    • Mitigating Risk Amid Layoff-Driven Confidential Witness BoomLAW360March 10, 2021
    • Non-U.S. Issuers Targeted in Securities Class Action Lawsuits Filed in US, Harvard Law School Forum, March 29, 2020
    • Global Securities Litigation Trends, Harvard Law School Forum, July 29, 2019
    • Recent Trends in Off-Shore Targeted US Class Actions, Harvard Law School Forum, April 30, 2019
    • INSIGHT: Life Sciences Companies Targeted in Securities Class Actions, Bloomberg, March 7, 2019
    • A New Era in Global Securities Litigation, NACD Directorship MagazineFebruary 22, 2018
    • A New Era In Global Securities Litigation, LAW360, February 16, 2018
    • Guard Attorney-Client Privilege When Sharing Legal Advice, LAW360, October 5, 2017
    • The Devil Is in the Details: A Litigator’s 5 Tips for Drafting Board Minutes, Corporate Counsel, January 26, 2017 
    • Delaware Courts Update: Supreme Court Issues Decision on Exculpatory Clauses, Wall Street Lawyer, June 2015
    • Economic Concepts in the Litigation Context, Practising Law Institute (October 19, 2023)
    • BioDech: A Global Life Sciences Broadcast Series (2023)
    • 2023 Securities Litigation and Enforcement Mid-Year Update –  The Knowledge Group (August 1, 2023)
    • GCB Corporate Governance Workshop, ChIPs Network (June 22, 2023)
    • WIIN Half-Day Retreat, The ESG Wave (May 25, 2023)
    • Women in Securities Litigation Network Judicial Panel, Skadden, Arps, Slate, Meagher & Flom LLP (May 17, 2023)
    • Women in Securities Litigation Expert Panel (February 13, 2023)
    • Recent Litigation Trends Impacting Private and Public Companies ACC Philadelphia (March 15, 2022)
    • Women in Securities Litigation Network and Kick-Off Event – Webinar (October 29, 2021)
    • The Rise of Special Purpose Acquisition Companies (SPACs): How to Minimize Securities Litigation Risks – The Knowledge Group Webinar (August 6, 2021)
    • The Ever Shifting Landscape of Special Purpose Acquisition Companies (SPAC) – ACC NY Webinar (April 27, 2021) 
    • SPAC Roundtable – Dechert LLP, Webinar (April 21, 2021)
    • Recent Developments: Securities Fraud Actions Against Life Sciences Companies - Webinar (March 4, 2021)
    • COVID-19 Coronavirus Business Impact: Securities Litigation, SEC Guidance and Strategies to Minimize Risk – Webinar (May 28, 2020)
    • Securities Class Actions: Navigating Halliburton II, Materiality and Price Impact Rule Issues – The Knowledge Group (September 12, 2019)
    • Risk Management and Recent Trends in Securities Fraud Litigation Against Life Sciences Companies - Webinar (April 17, 2019)
    • Securities and Shareholder Litigation: What Lies Ahead in 2019 – The Knowledge Group (February 19, 2019)
    • Securities Fraud Litigation Against Life Sciences Companies - Recent Trends - Webinar (June 15, 2018)
    • Developments in Securities Fraud Class Actions Against US Life Sciences Companies -  Webinar (May 11, 2017)
    • From the Boardroom to the Courtroom – A Price Worth Paying? - Omaha, NE (March 22, 2017)
    • From the Boardroom to the Courtroom – A Price Worth Paying? NIRI Annual Meeting (December 2016)
    • From the Boardroom to the Courtroom – A Price Worth Paying? Memphis, TN (November 15, 2016)
    • From the Boardroom to the Courtroom – A Price Worth Paying? Salt Lake City, UT (October 27, 2016)
    • From the Boardroom to the Courtroom – A Price Worth Paying? - Louisville, KY (May 19, 2016)
    • Class Actions Face Challenges At the Supreme Court - Chicago, IL (March 24, 2016)
    • From the Boardroom to the Courtroom – A Price Worth Paying? – Presented by the Chicago Network, Women Corporate Directors and Dechert LLP (June 16, 2014)
    • Co-founder and Advisory Committee Member, Women in Securities Litigation Network
    • Chicago Bar Association
    • American Bar Association